RxDoctor Payments Data

Dee Roach, MD

Family Medicine · Colorado City, TXNPI 1275542854

Payments from drug & device makers

$824in general payments, 2019–2025

Across 51 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211
  • Johnson & Johnson$154
  • Lilly USA, LLC$110
  • AbbVie$72
  • Amgen$45
  • Novartis$44
  • plus $189 from 9 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$824 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,321
Medicare patients
51
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide292$305,832
Trelegy ElliptaFluticasone/Umeclidin/Vilanter155$121,776
JardianceEmpagliflozin148$109,735
FarxigaDapagliflozin Propanediol127$102,998
Enbrel SureclickEtanercept13$94,054
EliquisApixaban130$68,098
JanuviaSitagliptin Phosphate61$37,313
XareltoRivaroxaban27$24,563
TrulicityDulaglutide21$22,164
NamzaricMemantine Hcl/Donepezil Hcl13$15,025
Breo ElliptaFluticasone/Vilanterol30$14,246
DapagliflozinDapagliflozin Propanediol32$12,057
Tresiba Flextouch U-200Insulin Degludec18$11,198
Combivent RespimatIpratropium/Albuterol Sulfate12$9,582
Gabapentin783$9,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$305,832292 claims
AstraZenecaFarxiga$26$102,998127 claims
PfizerEliquis$13$68,098130 claims
MerckJanuvia$11$37,31361 claims
Johnson & JohnsonXarelto$154$24,56327 claims
Lilly USA, LLCTrulicity$110$22,16421 claims
AbbVieNamzaric$72$15,02513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Colorado City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →